NCT05797727Completed
Real-Life Pilot Feasibility Study (LC_RLP)
LIFECHAMPS: A Collective Intelligence Platform to Support Cancer Champions Real-Life Pilot
Source: ClinicalTrials.gov · Last updated 1 Mar 2024
Brief summary (registry, in English)
The LifeChamps Real-Life pilot's objective is to ascertain the feasibility of the use of the LifeChamps solution, previously developed in another clinical trial, in a real-world environment. This solution integrates a health advisory system, and technical intelligence, based on behavioural science, to provide personalized recommendations to follow a healthier lifestyle, to act as a nutrition and physical activity coach, and to guide on social inclusion, among other issues, with the aim of increasing the quality of life. This study is conducted to investigate the feasibility of such an undertaking, assess the clinical impact it may have, as well as evaluate the applicability, usability, and effectiveness of the solution.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 121 (actual)
- First submitted
- 22 Mar 2023
- Start date
- 15 Jan 2023
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Aristotle University Of Thessaloniki
- Diseases
- Prostate cancer
- NCT number
- NCT05797727
What you commit to
- Study type: Interventional
- Participants enrolled: 121
- From 15 Jan 2023 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving chemotherapy.
Other illness
- Terminal cancer stage on palliative care.
Other
- Survival prognosis of \<18 months from the time of recruitment.
- Unwilling to provide written informed consent.
- Presence of internal medical device (e.g. pacemaker etc.)
Who the study is looking for
- Breast or prostate cancer.
- Diagnosed with early stage (I-III) cancer (breast, prostate) and living beyond initial cancer treatment (curative/incurable).
- Diagnosed with advanced or metastatic disease with life expectancy \>12 months.
- At least 1 month after a) local treatment with curative intent (surgery, radiotherapy) or b) initiation of systemic treatment (hormone treatment, CDK4/6 or new generation antiandrogens).
- Absence of diagnosed secondary malignancy.
- Deemed by a member of the multidisciplinary team as physically and psychologically fit to participate in the study.
- Able to read, write and understand the respective local language (greek).
- Achieve a score of above 2 on the Mini-Cog during the screening process.
- Able to bring and use own Android version 10 (or above) device during the study.
- Domestic 24/7 internet access via wi-fi and/or 4G mobile data (will be provided if unavailable).
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laboratory of Medical Physics and Digital Innovation, AUTH Coordinator of this site? Confirm its status | Thessaloniki | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.